Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
IPO Year: 2019
Exchange: NYSE
Website: envistaco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $23.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2024 | $20.00 | Underperform | Mizuho |
| 10/31/2024 | $16.00 → $23.00 | Underperform → Market Perform | Leerink Partners |
| 10/8/2024 | $20.00 | Equal Weight | Wells Fargo |
| 8/8/2024 | $23.00 → $16.00 | Overweight → Neutral | JP Morgan |
| 4/26/2024 | $33.00 → $21.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/26/2024 | $19.00 | Underperform | Leerink Partners |
| 2/9/2024 | $30.00 → $23.00 | Buy → Hold | Jefferies |
| 2/8/2024 | Outperform → Mkt Perform | William Blair | |
| 1/5/2024 | $26.00 | Neutral | UBS |
BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET. A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/. ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS
DALLAS, May 15, 2025 /PRNewswire/ -- Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (TSE: 6501), today announced a five-year agreement with Envista Holdings Corporation (NYSE:NVST) ("Envista"), a global leader in dental care, to deliver end-to-end IT managed services across Envista's operations in more than 60 countries. Following a highly competitive tendering process, Envista selected Hitachi Digital Services as its strategic IT partner to support its digital transformation and operational efficiency goals. Under this ag
BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%
BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca
BREA, Calif., Feb. 25, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") proudly announced that in 2024, the Envista Smile Project (Smile Project) contributed $1.8 million to further its mission of enhancing oral health accessibility for underserved communities. Since its inception in 2021, the Envista Smile Project has delivered over $4.2 million in dental goods and services, positively impacting approximately 32,000 individuals worldwide. In 2024, the Envista Smile Project: Supplied free dental care to more than 787 patients in the Dominican Republic.
BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2024. "In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO. "2024 was a transition year for our company. After a challenging first half, we took actions over the last two quarters to position ourselves for improved performance moving forward. While we still have much more to do, we're encourag
BREA, Calif., Feb. 4, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will hold a Capital Markets Day on Wednesday, March 5, from 9:00 a.m. to 12:00 p.m. EST. This event will include a management presentation followed by a question-and-answer session. In-person attendance requires advanced registration. Those interested in attending the event in person can contact [email protected] for more information. The event and corresponding presentation will be webcast and available for replay afterwards by visiting the Events and Presentations section of investors.envistaco.com.
BREA, Calif., Jan. 27, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista is moving the time of the conference call and will now discuss these results beginning at 2:30 PM PT on the same date. The call will last approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation an
BREA, Calif., Jan. 14, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year.
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th Company to host an Investor Day on January 28th in New York City MOUNTAIN VIEW, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary unaudited revenue for the quarter and year ended December 31, 20
SD - Envista Holdings Corp (0001757073) (Filer)
SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)
10-Q - Envista Holdings Corp (0001757073) (Filer)
8-K - Envista Holdings Corp (0001757073) (Filer)
DEFA14A - Envista Holdings Corp (0001757073) (Filer)
DEF 14A - Envista Holdings Corp (0001757073) (Filer)
SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)
SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)
10-K - Envista Holdings Corp (0001757073) (Filer)
SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)
BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%
BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca
BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2024. "In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO. "2024 was a transition year for our company. After a challenging first half, we took actions over the last two quarters to position ourselves for improved performance moving forward. While we still have much more to do, we're encourag
BREA, Calif., Jan. 27, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista is moving the time of the conference call and will now discuss these results beginning at 2:30 PM PT on the same date. The call will last approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation an
BREA, Calif., Jan. 14, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year.
BREA, Calif., Oct. 30, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the third quarter of 2024. For the quarter ended September 27, 2024, reported sales were $601.0 million. Core sales in the quarter declined 5.3% over the corresponding quarter in 2023. Net income in the third quarter was $8.2 million or $0.05 per diluted share, compared to net income of $21.5 million or $0.12 per diluted share in Q3 2023. Adjusted net income for the third quarter of 2024 was $21.1 million or $0.12 per diluted share, compared to adjusted net income
BREA, Calif., Oct. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its third quarter 2024 on Wednesday, October 30, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y
BREA, Calif., Aug. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the second quarter of 2024. For the quarter ended June 28, 2024, reported sales were $633.1 million. Core sales in the quarter declined 3.2% over the corresponding quarter in 2023. Net loss in the second quarter was $1,151.6 million or $6.69 per share. The net loss included a $1,153.8 million non-cash charge related to the impairment of goodwill and intangible assets. During the same period, adjusted net income was $18.5 million or $0.11 per diluted share compared
BREA, Calif., July 12, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2024 on Wednesday, August 7, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y
BREA, Calif., May 1, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the first quarter of 2024. For the quarter ended March 29, 2024, reported sales were $623.6 million. Core sales in the quarter increased 0.4% over the corresponding quarter in 2023. For the first quarter of 2024, net income was $23.6 million or $0.14 per diluted share. During the same period, adjusted net income was $45.8 million or $0.26 per diluted share compared to adjusted net income of $67.8 million or $0.38 per diluted share in the same period of 2023. Adjusted
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b
BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an
BREA, Calif., April 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) announced today the appointment of Paul Keel as Chief Executive Officer and a member of the Board of Directors effective May 1, 2024. He succeeds Amir Aghdaei, who will continue to support the transition as a senior advisor. "Paul's strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at this stage in our growth journey," said Scott Huennekens, chairman of Envista. "His pertinent combination of accelerating growth and operationa
BREA, Calif., Feb. 26, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) announced today that the Board of Directors and CEO Amir Aghdaei are formally launching a process to determine a successor for CEO. The Board of Directors has formed a search committee and retained an executive search firm to find qualified external candidates to lead the next phase of Envista. This process is expected to be completed this year. Mr. Aghdaei will remain President and CEO until his successor is appointed. "After nearly 10 years leading Danaher's Dental Platform and the Envista t
BREA, Calif., Dec. 14, 2023 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the expansion of its leadership team, with the recent appointments of Robert Befidi as President, Diagnostics; Suraj Satpathy as Chief Human Resources Officer; and Andrew Chen as Chief Information Officer. Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader. He has held several senior executive roles in the 3M Health Care Business Group, including leading Global M
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
SC 13G - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G - Envista Holdings Corp (0001757073) (Subject)
SC 13G - Envista Holdings Corp (0001757073) (Subject)
Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00
Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00
Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously
Wells Fargo initiated coverage of Envista with a rating of Equal Weight and set a new price target of $20.00
JP Morgan downgraded Envista from Overweight to Neutral and set a new price target of $16.00 from $23.00 previously
Morgan Stanley downgraded Envista from Overweight to Equal-Weight and set a new price target of $21.00 from $33.00 previously
Leerink Partners initiated coverage of Envista with a rating of Underperform and set a new price target of $19.00
Jefferies downgraded Envista from Buy to Hold and set a new price target of $23.00 from $30.00 previously
William Blair downgraded Envista from Outperform to Mkt Perform
UBS initiated coverage of Envista with a rating of Neutral and set a new price target of $26.00
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)